Myelin Basic Protein (68-82), Guinea Pig Research Applicatio

Myelin Basic Protein (68-82), Guinea Pig: Research Applications, Clinical Value, and Future Directions in Neuroimmunology

Introduction
Myelin Basic Protein (MBP) is a critical structural component of the myelin sheath, which insulates nerve fibers in the central nervous system (CNS) and is essential for rapid nerve impulse conduction. The peptide fragment MBP (68-82), derived from the guinea pig sequence, has gained prominence as a research tool in neuroimmunology, particularly in the study of demyelinating diseases such as multiple sclerosis (MS). This peptide is widely used to induce experimental autoimmune encephalomyelitis (EAE), an animal model that recapitulates many pathological and immunological features of MS (Gold et al., 2006, Nature Reviews Neuroscience).

Mechanistically, MBP (68-82) acts as an encephalitogenic epitope, capable of activating autoreactive T cells that mediate CNS inflammation and demyelination. The guinea pig MBP (68-82) sequence is highly immunogenic in rodents, making it a preferred antigen for EAE induction and for dissecting the molecular and cellular mechanisms underlying CNS autoimmunity (Miller et al., 2010, Journal of Neuroimmunology). This research paper provides a comprehensive overview of the clinical value, research applications, challenges addressed, supporting literature, experimental data, usage guidelines, and future directions for MBP (68-82), guinea pig, in neuroimmunological research.

[Related: ferrostatin-1 ferroptosis inhibitor] Clinical Value and Applications
The primary clinical value of MBP (68-82), guinea pig, lies in its utility as an experimental tool for modeling autoimmune demyelinating diseases. EAE, induced by immunization with MBP (68-82), serves as the gold standard preclinical model for MS research. This model enables the study of disease pathogenesis, the identification of immunological targets, and the preclinical evaluation of novel therapeutics (Robinson et al., 2014, Trends in Immunology).

Key applications include:
1. **Pathogenesis Studies:** MBP (68-82) facilitates the investigation of T cell-mediated autoimmunity, blood-brain barrier disruption, and neuroinflammation, which are central to MS pathology.
2. **Therapeutic Screening:** The EAE model is indispensable for testing immunomodulatory drugs, monoclonal antibodies, and small molecules targeting CNS inflammation.
3. **Biomarker Discovery:** MBP (68-82)-induced EAE allows for the identification of molecular and cellular biomarkers associated with disease onset, progression, and therapeutic response.
4. **Mechanistic Insights:** The peptide is used to dissect antigen processing, T cell receptor specificity, and the role of regulatory immune cells in CNS autoimmunity (Baxter, 2007, Journal of Neurochemistry).

[Related: trichostatin a (tsa)] Key Challenges and Pain Points Addressed
Current challenges in MS and related demyelinating disorders include the lack of curative therapies, incomplete understanding of disease mechanisms, and the need for reliable preclinical models. MBP (68-82), guinea pig, addresses several of these pain points:

- **Modeling Human Disease:** Human MS is a heterogeneous disease with complex immunopathology. MBP (68-82)-induced EAE provides a reproducible and well-characterized model that mirrors key aspects of MS, including relapsing-remitting and chronic-progressive courses (Steinman & Zamvil, 2006, Nature Medicine).
- **Antigen Specificity:** The use of a defined peptide epitope allows for precise interrogation of antigen-specific immune responses, which is challenging in spontaneous or less-defined models.
- **Therapeutic Validation:** EAE induced by MBP (68-82) is the benchmark for preclinical efficacy testing of immunotherapies, enabling translational research and reducing the risk of clinical trial failures.
- **Standardization:** Synthetic MBP (68-82) peptides offer batch-to-batch consistency, critical for reproducibility in experimental protocols.

[Related: amanitin] Literature Review
A substantial body of literature supports the use of MBP (68-82), guinea pig, in neuroimmunological research. Key studies include:

1. **Gold et al. (2006, Nature Reviews Neuroscience):** This review highlights the central role of MBP epitopes, including 68-82, in EAE induction and their relevance to MS immunopathology. The authors discuss the molecular mimicry and T cell activation mechanisms that underlie CNS autoimmunity.

2. **Miller et al. (2010, Journal of Neuroimmunology):** The study demonstrates the immunogenicity of MBP (68-82) in Lewis rats, showing robust T cell proliferation and CNS infiltration following immunization. The authors also detail the cytokine profiles associated with disease induction.

3. **Robinson et al. (2014, Trends in Immunology):** This article reviews advances in EAE models, emphasizing the utility of MBP (68-82) for dissecting effector and regulatory T cell functions. The authors underscore the translational value of the model for MS drug development.

4. **Baxter (2007, Journal of Neurochemistry):** Baxter discusses the biochemical properties of MBP peptides and their role in antigen presentation and T cell activation. The study provides insights into peptide processing and MHC binding.

5. **Steinman & Zamvil (2006, Nature Medicine):** This seminal paper reviews the history and evolution of EAE models, including the use of MBP (68-82), and their impact on understanding MS pathogenesis and therapy.

6. **Kawakami et al. (2004, Nature):** The authors use MBP (68-82) to track antigen-specific T cells in vivo, revealing their migration patterns and effector functions in the CNS.

7. **Lassmann et al. (2012, Acta Neuropathologica):** This review compares EAE models induced by different MBP peptides, highlighting the strengths and limitations of each for modeling distinct MS subtypes.

Experimental Data and Results
Experimental induction of EAE using MBP (68-82), guinea pig, typically involves immunization of susceptible rodent strains (e.g., Lewis rats) with the peptide emulsified in complete Freund’s adjuvant (CFA), often supplemented with pertussis toxin to enhance disease severity. Key findings from the literature include:

- **Disease Induction:** Immunization with MBP (68-82) leads to a monophasic or relapsing-remitting neurological syndrome characterized by ascending paralysis, weight loss, and CNS inflammation (Miller et al., 2010).
- **Immunopathology:** Histological analysis reveals perivascular infiltration of CD4+ T cells, macrophages, and demyelination in the spinal cord and brain (Gold et al., 2006).
- **Cytokine Profiles:** MBP (68-82)-specific T cells produce pro-inflammatory cytokines such as IFN-γ, TNF-α, and IL-17, mirroring the Th1/Th17 polarization observed in MS (Robinson et al., 2014).
- **Therapeutic Modulation:** Treatment with immunosuppressive agents (e.g., fingolimod, anti-CD20 antibodies) in MBP (68-82)-induced EAE models results in reduced clinical scores, decreased CNS infiltration, and preservation of myelin integrity (Steinman & Zamvil, 2006).
- **Antigen-Specific T Cell Tracking:** Kawakami et al. (2004) used MBP (68-82)-specific T cell receptor transgenic mice to visualize T cell migration and effector functions in real time, providing mechanistic insights into CNS autoimmunity.

Usage Guidelines and Best Practices
To ensure reproducibility and reliability in experiments utilizing MBP (68-82), guinea pig, the following guidelines are recommended:

1. **Peptide Preparation:** Dissolve MBP (68-82) in sterile phosphate-buffered saline (PBS) or water at the recommended concentration (typically 1–2 mg/mL). Avoid repeated freeze-thaw cycles to preserve peptide integrity.
2. **Immunization Protocol:** Emulsify the peptide with CFA at a 1:1 ratio. For Lewis rats, inject 100–200 μg of peptide subcutaneously at the base of the tail or flanks. For enhanced disease severity, administer pertussis toxin intraperitoneally on days 0 and 2 post-immunization.
3. **Animal Monitoring:** Assess animals daily for clinical signs of EAE using a standardized scoring system (0–5 scale). Provide supportive care and humane endpoints as per institutional guidelines.
4. **Controls:** Include vehicle and adjuvant-only control groups to account for non-specific effects.
5. **Batch Consistency:** Use synthetic peptides from reputable suppliers to ensure sequence fidelity and purity (>95%). Document lot numbers and storage conditions.
6. **Eth Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 50 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541566